Drug Resistance and Genotyping

Transmission of drug-resistant virus strains is well documented and associated with suboptimal virologic response to initial antiretroviral therapy (ART). The risk of acquiring drug-resistant virus is related to the prevalence of drug resistance in infected persons engaging in high-risk behaviors in a given community. Similarly drug resistance in Mycobacterium tuberculosis is growing concern in developing countries, hence information on drug resistance mutation is key in successful treatment.

SERVICES

MTB DRUG RESISTANCE (MTBDR)

It is a highly specific and sensitive assay for molecular detection of drug resistance and can detect all the known mutations responsible for drug resistance in MTB. Detection of RIF and INH resistance could also identify MDR strains.

MTB DRUG RESISTANCE- XDR

XDR-TB or extensively drug-resistant tuberculosis (TB), is a form of TB which is resistant to at least four of the core anti-TB drugs. We offer gold standard PCR and DNA sequencing based xDR-TB detection.

HBV GENOTYPING CORE AND PRECORE

This test detects mutations in the pre-core stop codon (G1896A) and the basal core promoter (A1762T and G1764A) which are responsible for clinical and virological features of patients with HBeAg-negative CHB.

HBV GENOTYPING DRUG RESISTANCE

Mutations in the HBV genome, and the HBV genotype itself, may affect treatment response and disease course. We offer PCR sequencing based detection of mutations in HBV polymerase gene responsible for drug resistance.

HCV GENOTYPING

The genotype of the hepatitis C virus (HCV) is an important indicator for antiviral therapeutic response. Hepatitis C Virus genotyping is performed to predict likelihood of therapeutic response and duration of treatment.

IL28B GENOTYPING (PEG-IFN & RBV)

The IL28B gene is involved in the immune response to certain viruses, including hepatitis C. There are three IL28B subtypes: CC, CT, and TT. People with the CC genotype have a stronger immune response to HCV infection than CT or TT.

HBV GENOTYPING CORE AND PRECORE

This test detects mutations in the pre-core stop codon (G1896A) and the basal core promoter (A1762T and G1764A) which are responsible for clinical and virological features of patients with HBeAg-negative CHB.

HIV-1 DRUG RESISTANCE PROTEASE INHIBITORS

This test is a guide for selection of antiretroviral drugs. This test detects HIV-1 mutations in the protease (Pr) gene. We offer PCR sequencing based detection of mutations in HIV-1 protease gene responsible for drug resistance.

HIV-1 DRUG RESISTANCE NRTI AND NNRTI

This test is prescribed for individuals with acute or established HIV-1 infection at entry or at failure of first line therapy. The test identifies mutations in HIV-1 reverse transcriptase gene and can guide selection of drugs.

IL28B GENOTYPING (PEG-IFN & RBV)

The IL28B gene is involved in the immune response to certain viruses, including hepatitis C. There are three IL28B subtypes: CC, CT, and TT. People with the CC genotype have a stronger immune response to HCV infection than CT or TT.

HIV-1 DRUG RESISTANCE INTEGRASE INHIBITORS

This test detects HIV-1 mutations in the Integrase (INT) gene. Mutations in integrase gene are responsible for resistance to integrase inhibitor drugs, hence the test can help in selection of integrase inhibitor drugs such as rategravir.

HIV-1 DRUG RESISTANCE INTEGRASE INHIBITORS

This test detects HIV-1 mutations in the Integrase (INT) gene. Mutations in integrase gene are responsible for resistance to integrase inhibitor drugs, hence the test can help in selection of integrase inhibitor drugs such as rategravir.

HIV-1 TROPISM TEST

HIV tropism refers to the cell type that the HIV infects and replicates in. HIV-1 tropism is performed by sequencing of V3 loop region from HIV-1 envelop gp120 gene. Viruses can be classified as X4, R5 or dual tropic using this test.

HPV GENOTYPE

HPV genotyping is important test for assessment and treatment of infection. Low-risk HPV types are typically associated with genital warts, whereas high-risk (HR) types are associated with invasive cervical cancer.

Interested in our work and services?

Leave your contact details and we will get back to you as earliest

×
Any questions? Get a call back
Get a Call Back